Alamar Biosciences partners with GSK on large-scale proteomics study
GSK•Alamar Biosciences entered a scientific collaboration with GSK to analyze more than 60,000 serum samples for protein signatures linked to disease progression, biological subtypes and treatment response.
1. Study details
The study will use Alamar Biosciences’ NULISAseq Immune 340 and NULISAseq Neuro 220 panels. Its findings aim to support earlier disease detection, patient stratification and targeted drug development across multiple disease areas.
